PT2668182T - Inibição de il-7 e de ifn gama para o tratamento de inflamação autoimune - Google Patents
Inibição de il-7 e de ifn gama para o tratamento de inflamação autoimuneInfo
- Publication number
- PT2668182T PT2668182T PT127030138T PT12703013T PT2668182T PT 2668182 T PT2668182 T PT 2668182T PT 127030138 T PT127030138 T PT 127030138T PT 12703013 T PT12703013 T PT 12703013T PT 2668182 T PT2668182 T PT 2668182T
- Authority
- PT
- Portugal
- Prior art keywords
- ifn
- treatment
- autoimmune inflammation
- gamma inhibition
- gamma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161437061P | 2011-01-28 | 2011-01-28 | |
| EP11152515 | 2011-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2668182T true PT2668182T (pt) | 2018-01-31 |
Family
ID=46577835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT127030138T PT2668182T (pt) | 2011-01-28 | 2012-01-27 | Inibição de il-7 e de ifn gama para o tratamento de inflamação autoimune |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8592456B2 (pt) |
| EP (1) | EP2668182B1 (pt) |
| JP (1) | JP5969505B2 (pt) |
| KR (1) | KR101875248B1 (pt) |
| CN (1) | CN103476771B (pt) |
| AR (1) | AR085040A1 (pt) |
| AU (1) | AU2012210489B2 (pt) |
| BR (1) | BR112013019011B1 (pt) |
| CA (1) | CA2825684C (pt) |
| DK (1) | DK2668182T3 (pt) |
| EA (1) | EA027351B1 (pt) |
| ES (1) | ES2664507T3 (pt) |
| IL (1) | IL227626A0 (pt) |
| MX (1) | MX353762B (pt) |
| MY (1) | MY162397A (pt) |
| PL (1) | PL2668182T3 (pt) |
| PT (1) | PT2668182T (pt) |
| RU (1) | RU2013139663A (pt) |
| SG (1) | SG192176A1 (pt) |
| TW (1) | TWI520955B (pt) |
| UA (1) | UA113160C2 (pt) |
| UY (1) | UY33884A (pt) |
| WO (1) | WO2012101261A1 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5883034B2 (ja) * | 2011-01-28 | 2016-03-09 | ４エスツェー ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツング | 自己免疫性炎症の治療のためのＩＬ１７及びＩＦＮ−γ阻害 |
| US9156837B2 (en) | 2011-07-29 | 2015-10-13 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2013116682A1 (en) | 2012-02-02 | 2013-08-08 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| SG11201407919WA (en) | 2012-05-31 | 2014-12-30 | Phenex Pharmaceuticals Ag | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma] |
| JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
| CN104978732A (zh) * | 2014-04-11 | 2015-10-14 | 中国船舶工业系统工程研究院 | 一种摄像机参数标定板 |
| AU2015258859B2 (en) | 2014-05-15 | 2020-07-23 | Rani Therapeutics, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| RU2580301C1 (ru) * | 2015-04-21 | 2016-04-10 | Людмила Николаевна Хон | Способ лечения системной красной волчанки человека |
| LT3679034T (lt) | 2017-09-06 | 2022-09-12 | Immunic Ag | 1-(4-(izoksazol-5-il)-1h-pirazol-1-il)-2-metilpropan-2-olio dariniai ir susiję junginiai, kaip il-7 ir ifn- gama inhibitoriai, skirti autoimuninių ligų ir lėtinių uždegimų gydymui |
| WO2019223718A1 (zh) * | 2018-05-22 | 2019-11-28 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2021027729A1 (zh) * | 2019-08-09 | 2021-02-18 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN112341519A (zh) * | 2019-08-09 | 2021-02-09 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN112341442B (zh) * | 2019-08-09 | 2021-10-22 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN112341435B (zh) * | 2019-08-09 | 2021-10-22 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2023281097A1 (en) | 2021-07-09 | 2023-01-12 | Immunic Ag | Methods for treating cancer |
| WO2023198873A1 (en) | 2022-04-14 | 2023-10-19 | Immunic Ag | Deuterated rorgamma/rorgammat inverse agonists |
| WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0610744B1 (en) * | 1993-02-09 | 1998-11-04 | Bayer Corporation | Sulfonamide aminomethylene derivatives as immunosuppressants |
| US6100260A (en) * | 1997-04-21 | 2000-08-08 | Sumitomo Pharmaceutical Company, Limited | Isoxazole derivatives |
| JP3237608B2 (ja) * | 1997-04-21 | 2001-12-10 | 住友製薬株式会社 | イソキサゾール誘導体 |
| EP0979226B1 (en) * | 1997-04-21 | 2005-11-09 | Sumitomo Pharmaceuticals Company, Limited | Isoxazole derivatives |
| US20060089398A1 (en) * | 2003-03-19 | 2006-04-27 | Gang Liu | Isoxazole carboxamide derivatives as ghrelin receptor modulators |
| RS50796B (sr) * | 2004-03-09 | 2010-08-31 | Boehringer Ingelheim Pharmaceuticals Inc. | 3-[4-heterociklil-1,2,3-triazol-1-il]-n-aril-benzamidi kao inhibitori produkcije citokina za lečenje hroničnih inflamatornih oboljenja |
| TW200826936A (en) * | 2006-12-01 | 2008-07-01 | Merck Frosst Canada Ltd | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| EP2350064A1 (en) * | 2008-10-01 | 2011-08-03 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| AR076984A1 (es) * | 2009-06-08 | 2011-07-20 | Merck Serono Sa | Derivados de pirazol oxadiazol |
| JP5883034B2 (ja) * | 2011-01-28 | 2016-03-09 | ４エスツェー ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツング | 自己免疫性炎症の治療のためのＩＬ１７及びＩＦＮ−γ阻害 |
-
2012
- 2012-01-27 MX MX2013008718A patent/MX353762B/es active IP Right Grant
- 2012-01-27 SG SG2013057237A patent/SG192176A1/en unknown
- 2012-01-27 MY MYPI2013002812A patent/MY162397A/en unknown
- 2012-01-27 ES ES12703013.8T patent/ES2664507T3/es active Active
- 2012-01-27 CN CN201280010668.3A patent/CN103476771B/zh active Active
- 2012-01-27 CA CA2825684A patent/CA2825684C/en active Active
- 2012-01-27 EP EP12703013.8A patent/EP2668182B1/en active Active
- 2012-01-27 RU RU2013139663/04A patent/RU2013139663A/ru not_active Application Discontinuation
- 2012-01-27 PT PT127030138T patent/PT2668182T/pt unknown
- 2012-01-27 KR KR1020137022372A patent/KR101875248B1/ko active IP Right Grant
- 2012-01-27 JP JP2013550893A patent/JP5969505B2/ja active Active
- 2012-01-27 AU AU2012210489A patent/AU2012210489B2/en active Active
- 2012-01-27 PL PL12703013T patent/PL2668182T3/pl unknown
- 2012-01-27 WO PCT/EP2012/051357 patent/WO2012101261A1/en active Application Filing
- 2012-01-27 DK DK12703013.8T patent/DK2668182T3/da active
- 2012-01-27 BR BR112013019011-6A patent/BR112013019011B1/pt active IP Right Grant
- 2012-01-27 EA EA201300862A patent/EA027351B1/ru not_active IP Right Cessation
- 2012-01-27 US US13/360,050 patent/US8592456B2/en active Active
- 2012-01-27 UA UAA201310314A patent/UA113160C2/uk unknown
- 2012-01-30 TW TW101102962A patent/TWI520955B/zh active
- 2012-01-30 AR ARP120100297A patent/AR085040A1/es active IP Right Grant
- 2012-01-30 UY UY0001033884A patent/UY33884A/es not_active Application Discontinuation
-
2013
- 2013-09-10 IL IL227626A patent/IL227626A0/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE036027T2 (hu) | IL17 és IFN-gamma inhibitorok autoimmun gyulladás kezelésére | |
| PL2668182T3 (pl) | Inhibitowanie IL17 i IFN-gamma do leczenia zapalenia autoimmunologicznego | |
| IL273815B (en) | Secondary vaccine particles for the treatment of inflammation | |
| IL261768B (en) | Devices and methods for tissue treatment | |
| TWI560200B (en) | Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders | |
| EP2709562A4 (en) | FABRIC BACKUP DEVICES AND USE METHOD THEREFOR | |
| HK1202244A1 (en) | Prebiotic formulations and methods of use | |
| EP2741804A4 (en) | SYSTEM AND METHOD FOR PROCESSING MEMBERS | |
| HK1199015A1 (en) | Treatment of inflammation | |
| IL229079A0 (en) | Methods and compositions using 4pde inhibitors for the treatment and management of autoimmune and inflammatory diseases | |
| EP2688594A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| EP2723347A4 (en) | PREVENTING AND TREATING INFLAMMATORY DISEASES | |
| EP2574172A4 (en) | MATERIALS AND METHOD FOR TREATING INFLAMMATION | |
| EP2866830A4 (en) | ANTI-CXCL9, ANTI-CXCL10, ANTI-CXCL11, ANTI-CXCL13, ANTI-CXCR3 AND ANTI-CXCR5 AGENTS FOR THE INHIBITION OF INFLAMMATION | |
| EP2694079A4 (en) | POLYMERS AND METHOD FOR PAIN TREATMENT | |
| EP2741771A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | |
| EP2575824A4 (en) | METHODS FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES | |
| HK1203430A1 (en) | Bisarylsulfonamides useful in the treatment of inflammation and cancer | |
| EP3603631C0 (en) | METHODS AND COMPOSITIONS FOR TREATING DIVERTICULOSIS | |
| HK1210209A1 (en) | Treatment of diseases of endothelial dysfunction and inflammation | |
| ZA201306087B (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation | |
| HK1207293A1 (en) | Composition for the treatment of inflammatory and immune disorders | |
| ZA201408045B (en) | Compositions and methods for the treatment of inflammation and lipid disorders | |
| HK1194977A1 (zh) | 奈妥比坦與帕洛諾司瓊的具療效的組合 | |
| GB201100651D0 (en) | Treatment of inflammation |